Yükleniyor... / Loading...
This study investigates the value of the PD-L1 protein as a biomarker (disease-related marker) across various cancers and blood diseases. It included previously untreated patients aged 18-75 with confirmed disease such as diffuse large B-cell lymphoma. It is an observational (non-phase) study and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: General inclusion criteria : * Age ≥ 18 years and ≤ 75 years, * Life expectancy more than 4 months * Signed informed consent obtained * Social security affiliation is mandatory * Non previously treated (even by corticotherapy), * HIV negative, HBs negative, HCV negative Inclusion criteria for DLBCL patients : * A biopsy proven diagnosis of de novo DLBCL according to the current WHO criteria, * Immunohistochemistry for GCB/nonGC classification according to Hans' algorithm * Patients with advanced-stage disease defined as Ann Arbor stages III or IV, or stages I or II with bulky disease (\>7cm) Inclusion criteria for non-small cell lung cancer patients : * A biopsy proven diagnosis of de novo non-small cell lung cancer (all stages) according to the current WHO criteria Inclusion criteria for Hodgkin's lymphoma patients : * A biopsy proven diagnosis of Hodgkin's lymphoma according to the current WHO criteria Inclusion criteria for metastatic breast cancer or with lymph node involvement : * A biopsy proven diagnosis infiltrating lobular or ductal breast carcinoma * with lymph node involvement or metastasis Inclusion criteria for patients with immune thrombocytopenia (ITP) : * Primary ITP was defined by the IWG as a platelet count less than 100 G/L in the absence of other causes or disorders that may be associated with thrombocytopenia. * Bone marrow examination excluding a central aetiology of thrombocytopenia Inclusion criteria for healthy volunteers : \- Inclusion criteria for blood donation according to the Etablissement Français du Sang (EFS) criteria Exclusion Criteria: General non-inclusion criteria : * Age \< 18 years et \> 75 years, * Pregnant women, * Person legally involved in a case * No social security affiliation * Signed informed consent not obtained, * Preliminary treatment (even corticoid treatment). * HIV positive, HBs positive, HCV positive Non-inclusion criteria for DLBCL patients : * Lymphoma other than DLBCL, * Transformation of a low grade lymphoma to a high grade lymphoma (DLBCL), * Extranodal marginal zone lymphoma of MALT lymphoma, * Post-transplant lymphoproliferative disorders, * Lymphoblastic lymphoma, * Burkitt's lymphoma, * Carcinoma or history of carcinoma except in situ cervical carcinoma. Non-inclusion criteria for non-small cell lung cancer patients : None Non-inclusion criteria for Hodgkin patients : \- Non Hodgkin's lymphoma Non-inclusion criteria for metastatic breast cancer or with lymph node involvement : * Carcinoma other than infiltrating lobular or ductal breast carcinoma * Chemotherapy in 30 days preceding the inclusion * Hormonotherapy in 7 days preceding the inclusion * Carcinoma or history of carcinoma except in situ cervical carcinoma. * Hemoglobin level \< 10g/dl Non-inclusion criteria for patients with immune thrombocytopenia (ITP) : \- Central aetiology of the thrombocytopenia Non-inclusion criteria for healthy volunteers : \- Exclusion criteria for blood donation according to the Etablissement Français du Sang (EFS) criteria